MedTrace Logo

MB-CART20.1 Melanoma

NCT03893019 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-05-16

No results posted yet for this study

Summary

This is a phase l multi-centric, single arm, prospective, open, dose-escalation study in patients with unresectable stage III oder IV melanoma. The trial will include 15 adult patients. The trial is a classic 3+3 design with 1 Log dose increments and maximum 3 dose levels of the intravenously administered MB-CART20.1.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

MB-CART20.1

MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells

Sponsors & Collaborators

  • DLR German Aerospace Center

    collaborator OTHER

  • Miltenyi Biomedicine GmbH

    lead INDUSTRY

Principal Investigators

  • Peter Borchmann, Prof. · Universitätsklinikum Köln

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-08
Primary Completion
2023-01-30
Completion
2023-01-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03893019 on ClinicalTrials.gov